Summary Non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) differ significantly in their clinical response to topoisomerase lla (topo-lla)-directed drugs, such as etoposide and teniposide, as NSCLC is virtually insensitive to single-agent therapy, while SCLC responds in two-thirds of cases. Preclinical studies have indicated that resistance to topo-lla drugs depends on topo-lIa content and/or activity, the altered-topo-l1 multidrug resistance phenotype (at-MDR) and/or one of two different drug efflux pumps, P-glycoprotein (P-gp) and the multidrug resistance protein (MRP). Immunohistochemical analysis on paraffin-embedded tissue from 27 cases of untreated NSCLC and 29 cases of untreated SCLC (of which additional tumour biopsies after treatment with topo-lla-directed drugs were available in ten cases) yielded the following results: NSCLC had significantly less topo-lla than SCLC (P < 0.0001), as only 5 out of 27 NSCLC cases had > 5% positive cells compared with 28 out of 29 SCLC, and 0 out of 27 NSCLC had > 25% positive cells compared with 26 out of 29 SCLC. P-gp was detected in > 5% of cells in only 3 out of 27 NSCLC and in 6 out of 29 SCLC, and MRP in 5 out of 27 of NSCLC and 9 out of 29 SCLC. After treatment of patients with SCLC with either etoposide or teniposide, which are topo-lla-directed drugs, there was an increase in MRP (P < 0.1) and P-gp (P < 0.05) positivity, while topo-lla decreased (P < 0.05). In conclusion, the major difference between untreated NSCLC and SCLC was in topo-lla content. In the small series of ten patients treated for SCLC, all three MDR phenotypes appeared to increase.
The treatment of lung cancer depends on whether the tumour has a small-cell (SCLC) or non-small-cell (NSCLC) histology. SCLC tumours are initially sensitive to drugs such as etoposide, which acts on the nuclear enzyme DNA topoisomerase Ila (topo-IlIa) by freezing an enzyme-DNA cleavable complex and thereby creating DNA breaks, eventually leading to cell death. Such DNAdamaging drugs are termed topo-II poisons as they convert an essential enzyme to a lethal one (Chen and Liu, 1994) . Despite initial response rates of 70-80%, patients with SCLC usually relapse with a clinically drug-resistant tumour, and the 2-year survival is only approximately 5% (Hansen, 1992) . Extensive experimental research has documented the existence of several cellular resistance mechanisms towards topo-LI poisons such as etoposide, namely either a reduction and/or mutation in the enzyme itself, called the altered topoisomerase 11 multidrug resistance phenotype (at-MDR) (Pommier et al, 1986; Danks et al, 1988) , or two well-characterized drug efflux pumps, P-glycoprotein (P-gp) (Borst et al, 1993) and MRP (Cole et al, 1992) , both of which have been shown in transfection studies to be sufficient to confer resistance. The aim of the present study was to study the expression of these three factors, topo-IIa, P-gp and MRP, in the different histological types of lung cancer and in addition to investigate whether changes in their incidence occurred in SCLC after treatment with etoposide or teniposide.
Nine consecutive cases of each of the main subtypes of NSCLC [i.e. nine squamous cell carcinoma (SCC), nine adenocarcinoma (AC), nine large-cell carcinoma (LC)] obtained by surgical resection and 29 cases of SCLC obtained by endobronchial biopsy or from mediastinal lymph nodes were examined. All tumour tissue was archival and had been formalin fixed for various time periods before being paraffin embedded. The SCLC patients had a mean age of 57 years, an equal male-female ratio and a mean survival after treatment of 13.4 months. Complete and partial responses were obtained in ten and eight patients, respectively, yielding a total response rate of 62%. In 10 of the 29 SCLC cases, archival tumour tissue was available after treatment with regimens that included either etoposide or teniposide.
Immunohistochemistry
Monoclonal antibodies towards topo-Ila (KiS1) (Boege et al, 1995) were a gift from Professor Kreipe, University of Wurzburg, Germany, as well as being purchased from Boehringer Mannheim, Germany. Antibodies towards P-gp (JSB-1) (Broxterman et al, 1989) were purchased from Sanbio, The Netherlands. Antibodies towards MRP (MRPrl) (Flens et al, 1994) were a gift from Professor R Scheper, Free University, Amsterdam, The Netherlands.
Paraffin sections (5 ,um) were deparaffinated in coconut oil at 60°C for 20 min and hydrated through ethanol-water dilutions. Antigen retrieval was performed by treatment in a microwave oven for 2 x 5 min in citrate buffer at 700 W. Endogenous peroxidase was blocked by 3% hydrogen peroxide for 5 min followed by 5 min in Tris-buffered saline (TBS: 50 mm Tris, 150 mM sodium chloride, pH 7.6). After a further incubation with 1% TBS-bovine serum albumin (BSA) for 10 min, sections were incubated overnight in a humidified chamber at 4°C with primary antibody diluted in 0.25% TBS-BSA at the following concentrations: MRPrl at 1:50, JSB-1 at 1:300 and KiSl at 1:10 000. After three 5-min washes in TBS, detection of the primary antibody was performed with the ABC duet kit from Dako (Ballerup, Denmark) according to the manufacturer's instructions. 3-Amino-9-ethylcarbazole in 0.05 M buffered acetic acid (pH 5.0) was used as chromogen. As a positive control, human small-cell H69/VP cells were formalin fixed, spun down into a pellet and paraffin embedded. H69NVP cells overexpress both P-gp and MRP in low to moderate degrees (Brock et al, 1995) . Furthermore, they have an extranuclear localization of topo-IlIa, which is useful as a specific positive control (Wessel et al, 1997) . As negative controls, wild-type H69 cells, which do not express P-gp or MRP and which have a nuclear localization of topo-IIa, were used. These control cells together with negative controls with omission of primary antibody were used in each staining reaction. aProportion of topo-lla-positive tumour cells is significantly lower than in SCLC (see Table I ) (P < 0.0001, Mann-Whitney test).
Stained sections were twice evaulated blindly by two participants (JK, MSe) and the percentage of positive tumour cells collected by class as 0, > 0-5%, 6-25%, 26-50%, > 51% from several fields depending on the size of the biopsy. Intraobserver and interobserver variation was < 10% and never more than one step. In these few cases of minor disagreement, a consensus was reached before the code was broken. Intensity of the staining reaction was not evaluated.
Statistics
The Mann-Whitney sum rank test was used in the statistical analysis comparing scores of samples from SCLC and NSCLC. Analyses on sequential SCLC biopsies were performed using Wilcoxon's matched-pairs signed-rank sum test.
RESULTS

Topo-Illa
The topo-Iloc immunostaining was seen in a mainly nuclear localization as well as a chromosomal localization in mitosis (Figures 1  and 2 ). As shown when comparing Tables 1 and 2 , there was a marked and significant (P < 0.0001) difference in the proportion of tumour cells stained in SCLC vs NSCLC, for which 5 out of 27
Figure 3 P-gp in SCLC demonstrating a mainly punctate 'Golgi' stain in tumour cells, although a membraneous stain is also seen. Primary magnification x 250 NSCLC cases had > 5% positive cells compared with 28 out of 29 SCLC, and 0 out of 27 NSCLC had > 25% positive cells compared with 26 out of 29 SCLC. In the series of pre-and post-treatment SCLC specimens, a decrease was observed in seven out of ten cases (P < 0.05) ( Table 3 ). Topo-IIax was not observed in an extranuclearonly localization, a possible resistance mechanism due to loss of the enzyme's nuclear localization signal (Harker et al, 1995; Mirski and Cole, 1995; Wessel et al, 1997) , either before or after treatment. Topo-IIax was only rarely observed in non-malignant cells in lymphoid tissue or in basal bronchial epithelial cells.
P-gp
The immunostaining for P-gp was mostly seen in a punctate 'Golgi-like' pattern in tumour cells (Figure 3) . However, in areas with high staining intensity, a plasma membrane reaction was also seen. An intracellular progression in sublines of increasing resistance from a punctate to a membraneous staining reaction of P-gp by the JSB-1 antibody was described in Broxterman et al (1989) . The incidence of P-gp was equal in untreated NSCLC and SCLC (Tables 1 and 2) as it was detected in > 5% of cells in only 3 out of 27 NSCLC and in 6 out of 29 SCLC. An increase in its frequency was observed in six out of ten SCLC patients after treatment (P < 0.05), being marked in two cases with increases from 0% to above 50% of tumour cells positive (Table 3 ). In non-malignant tissue, P-gp was often observed in superficial bronchial epithelium and in a few cases of NSCLC also in endothelial cells.
MRP
MRP was also found in roughly the same low proportion of untreated NSCLC and SCLC cells, namely in 5 out of 27 and 9 out of 29 cases with > 5% positive tumour cells respectively (Tables 1  and 2 ). In NSCLC subtypes, high MRP expression was noted in SCC (Table 2) . In tumour cells, MRP exhibited a membraneous stain. In non-malignant cells, MRP was often seen in superficial bronchial epithelium, however, in contrast to P-gp, MRP was also commonly observed in macrophages and scattered lymphocytes (Figure 4 ), in agreement with a study using mRNA in situ hybridization (Thomas et al, 1994) . In SCLC, after treatment, an increase in the proportion of positive cells was observed in four (Cole et al, 1992; Borst et al, 1993) , or changes in their drug target topo-IIa, namely at-MDR (Pommier et al, 1986; Danks et al, 1988) . The latter, which was first described in a SCLC cell line by de Jong et al (1990) , usually exists as a down-regulation of enzyme amount, but can also be due to mutations leading to a decreased drug sensitivity. (Yamazaki et al, 1996) . The appropriate method of detection of these drug resistance markers has been the subject of considerable debate , and it is recommended to use two different assays, such as RT-PCR for specificity and quantification and immunohistochemistry for localization (Beck et al, 1996) . This is not possible in a retrospective study on small tissue samples, such as the present study, as there is too little extractable mRNA in the paraffin-embedded sections (not shown). Another, more troubling problem in the use of sensitive mRNA detection techniques is the existence of P-gp and MRP proteins in normal tissue, such as bronchial epithelium, and especially the very strong positivity for MRP seen in macrophages (Figure 4) , where the inclusion of a few such cells would be enough to skew a whole tumour sample. In this respect, a mRNA and/or catalytic assay for topo-Ila should be more dependable as this protein is, for practical purposes, only found in tumour tissue. Both P-gp and MRP have been detected in SCLC and NSCLC, although their clinical importance is still undecided (Volm et al, 1991; Holzmayer et al, 1992; Segawa et al, 1993; Tabata et al, 1993; Abe et al, 1994; Oberli-Schrammli et al, 1994; Peoch et al, 1994; Thomas et al, 1994; Ota et al, 1995; Sugarawa et al, 1995; Beer et al, 1996; Chuman et al, 1996; Giaccone et al, 1996; Narasaki et al, 1996; Nooter et al, 1996; Stammler et al, 1996) . In the present study, their incidence was equal in untreated SCLC and NSCLC (Tables 1 and 2 ), indicating that these drug efflux pumps are not themselves responsible for the very different sensitivities to etoposide in these two diseases. However, when analysing their frequency in subtypes of NSCLC, it is interesting that both our (Table II) and a previous study (Ota et al, 1995) detected an increased level of MRP in SCC relative to other histological subtypes. This was, however, not the case when an mRNA assay was used (Sugarawa et al, 1995) , a result which could be due to admixture of MRP mRNA from macrophages and lymphocytes (Thomas et al, 1994; Figure 4) . The highly significant difference in topo-Ila content between untreated SCLC and NSCLC (Tables 1  and 2 ) is therefore remarkable. Similar results using another topoIIa-directed antibody on formalin-fixed tissue from 17 SCLC and 24 NSCLC was recently described with a topo-IIa index (proportion of positive cells per 1000 cells) of 0.60 for SCLC and 0.31 for NSCLC (Guinee et al, 1996) . It would therefore be of interest to study whether neuroendocrine AC, which has a better response to topo-II drugs than AC, has increased topo-IIa. Interestingly, four immunohistochemical studies on topo-IIa expression in breast cancer (Kreipe et al, 1993; Tuccari et al, 1993; Hellemans et al, 1995; Jarvinen et al, 1996) , two of which used the same KiS 1 antibody as in the present study (Kreipe et al, 1993; Jarvinen et al, 1996) , all demonstrated a mean/median positive reaction in 10-20% of tumour cells, thus higher than what we observed for NSCLC but much less than that for SCLC (Tables 1 and 2 ). This correlates with the clinical observation that the response of breast cancer to topo-IIa-targeted drugs is somewhere between that of NSCLC and that of SCLC. The present study included ten SCLC patients for whom tumour material before and after treatment was available. There was an increase in both P-gp and MRP expression, the former being most marked (Table 3) . A similar increase in P-gp expression in SCLC after treatment has previously been reported by Segawa et al (1993) using immunohistochemistry and the C219 antibody, while an increase in MRP expression or decrease in topo-IIa content after treatment (Table 3) has not, to our knowledge, been reported previously. It is quite possible that the lower topo-IIa expression reflects a lower growth rate. However, whether a decrease in topoIla is due to a decrease in the S/G2M fraction, to a specific downregulation of its promotor or to a post-translational modification, the end result of a decrease in the specific target enzyme is the same. A large body of evidence using cell lines and yeast indicates that it is the fluctuation of enzyme level that is critical for cytotoxicity (Webb et al, 1991; Nitiss et al, 1993) . Further, when the transcription factor E2F-1 is induced in stably transfected cells, thus increasing the S-phase fraction, topo-IIa levels increase, as do etoposide-induced DNA single-strand breaks and cytotoxicity (Hofland et al, 1997) . Thus cytotoxicity within a single cell line is usually tightly linked to enzyme levels, the exceptions being druginduced mutations, which usually occur after there has been a reduction in enzyme level, i.e. at higher levels of resistance. Whether this link between enzyme content and and sensitivity is also effective in clinical solid tumours is as yet unknown.
Thus, in conclusion, pretreatment levels of topo-IIa appear to play a greater role than P-gp and MRP in determining the differential sensitivity of SCLC and NSCLC to drugs such as etoposide and teniposide. Although only examined in a small series of ten patients, the results indicate that all three known MDR phenotypes increase after treatment for SCLC, with the changes in P-gp expression being the most pronounced. ABBREVIATIONS AC, adenocarcinoma; at-MDR, altered topoisomerase II MDR; BSA, bovine serum albumin; LC, large-cell carcinoma; MDR, multidrug resistance; MRP, multidrug resistance protein; P-gp, P-glycoprotein; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; TBS, tris-buffered saline; topo, topoisomerase
